Low-dose aspirin, statins, and metformin and survival in patients with breast cancers: a Norwegian population-based cohort study.
Breast cancer
Cohort
Low-dose aspirin
Metformin
Population-based
Statins
Survival
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
30 08 2023
30 08 2023
Historique:
received:
15
06
2023
accepted:
14
08
2023
medline:
1
9
2023
pubmed:
31
8
2023
entrez:
30
8
2023
Statut:
epublish
Résumé
Previous studies assessed the prognostic effect of aspirin, statins, and metformin in breast cancer (BC) patients, with inconclusive results. We performed a nationwide population-based cohort study to evaluate if post-diagnostic use of low-dose aspirin, statins, and metformin was associated with BC-specific survival. Women aged ≥ 50 years and diagnosed with BC in 2004-2017, who survived ≥ 12 months after diagnosis (follow-up started 12 months after diagnosis), were identified in the Cancer Registry of Norway. The Norwegian Prescription Database provided information on prescriptions. Multivariable Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between post-diagnostic use and BC-specific survival, overall and by oestrogen receptor (ER) status. A total of 26,190 patients were included. Of these, 5324 (20%), 7591 (29%), and 1495 (6%) were post-diagnostic users of low-dose aspirin, statins, and metformin, respectively. The median follow-up was 6.1 years, and 2169 (8%) patients died from BC. HRs for use, compared to no use, were estimated at 0.96 (95% CI 0.85-1.08) for low-dose aspirin (ER+: HR = 0.97, 95% CI 0.83-1.13; ER-: HR = 0.97, 95% CI 0.73-1.29, p value for interaction = 0.562), 0.84 (95% CI 0.75-0.94) for statins (ER+: HR = 0.95, 95% CI 0.82-1.09; ER-: HR = 0.77, 95% CI 0.60-1.00, p value for interaction = 0.259), and 0.70 (95% CI 0.51-0.96) for metformin (compared to use of non-metformin antidiabetics) (ER+: HR = 0.67, 95% CI 0.45-1.01; ER-: HR = 1.62, 95% CI 0.72-3.62, p value for interaction = 0.077). We found evidence supporting an association between post-diagnostic use of statins and metformin and survival, in patients with BC. Our findings indicate potential differences according to ER status.
Sections du résumé
BACKGROUND
Previous studies assessed the prognostic effect of aspirin, statins, and metformin in breast cancer (BC) patients, with inconclusive results.
METHODS
We performed a nationwide population-based cohort study to evaluate if post-diagnostic use of low-dose aspirin, statins, and metformin was associated with BC-specific survival. Women aged ≥ 50 years and diagnosed with BC in 2004-2017, who survived ≥ 12 months after diagnosis (follow-up started 12 months after diagnosis), were identified in the Cancer Registry of Norway. The Norwegian Prescription Database provided information on prescriptions. Multivariable Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association between post-diagnostic use and BC-specific survival, overall and by oestrogen receptor (ER) status.
RESULTS
A total of 26,190 patients were included. Of these, 5324 (20%), 7591 (29%), and 1495 (6%) were post-diagnostic users of low-dose aspirin, statins, and metformin, respectively. The median follow-up was 6.1 years, and 2169 (8%) patients died from BC. HRs for use, compared to no use, were estimated at 0.96 (95% CI 0.85-1.08) for low-dose aspirin (ER+: HR = 0.97, 95% CI 0.83-1.13; ER-: HR = 0.97, 95% CI 0.73-1.29, p value for interaction = 0.562), 0.84 (95% CI 0.75-0.94) for statins (ER+: HR = 0.95, 95% CI 0.82-1.09; ER-: HR = 0.77, 95% CI 0.60-1.00, p value for interaction = 0.259), and 0.70 (95% CI 0.51-0.96) for metformin (compared to use of non-metformin antidiabetics) (ER+: HR = 0.67, 95% CI 0.45-1.01; ER-: HR = 1.62, 95% CI 0.72-3.62, p value for interaction = 0.077).
CONCLUSION
We found evidence supporting an association between post-diagnostic use of statins and metformin and survival, in patients with BC. Our findings indicate potential differences according to ER status.
Identifiants
pubmed: 37649039
doi: 10.1186/s13058-023-01697-2
pii: 10.1186/s13058-023-01697-2
pmc: PMC10466817
doi:
Substances chimiques
Metformin
9100L32L2N
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Aspirin
R16CO5Y76E
Receptors, Estrogen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
BMC Cancer. 2019 Jan 11;19(1):54
pubmed: 30634941
J Clin Oncol. 2010 Mar 20;28(9):1467-72
pubmed: 20159825
J Natl Cancer Inst. 2020 Aug 1;112(8):839-846
pubmed: 31848605
Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):898-904
pubmed: 25791705
PLoS One. 2014 Oct 20;9(10):e110231
pubmed: 25329299
Breast Cancer Res. 2014 Apr 04;16(2):R34
pubmed: 24708725
Acta Oncol. 2020 Sep;59(9):1110-1117
pubmed: 32478629
Cancer. 2021 Nov 15;127(22):4142-4150
pubmed: 34342892
Cancer Med. 2014 Aug;3(4):1025-34
pubmed: 24944108
Int J Cancer. 2019 Mar 15;144(6):1251-1261
pubmed: 30367449
Sci Transl Med. 2023 Apr 26;15(693):eadf1147
pubmed: 37099632
Breast Cancer Res Treat. 2007 Jan;101(2):191-7
pubmed: 16823508
Diabetes Care. 2013 Oct;36(10):3018-26
pubmed: 23633525
Breast Cancer Res. 2018 Nov 20;20(1):142
pubmed: 30458873
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Natl Cancer Inst. 2011 Oct 5;103(19):1461-8
pubmed: 21813413
BMC Cancer. 2016 Aug 04;16:600
pubmed: 27491389
Cancer Epidemiol. 2017 Apr;47:20-27
pubmed: 28088656
Cancer. 2012 Mar 1;118(5):1202-11
pubmed: 21800293
Annu Rev Med. 2015;66:17-29
pubmed: 25386929
Front Pharmacol. 2023 Feb 15;14:1099810
pubmed: 36874020
Curr Oncol Rep. 2017 Jul;19(7):48
pubmed: 28597105
Pharmacoepidemiol Drug Saf. 2022 Mar;31(3):261-269
pubmed: 35019190
Cancer Treat Rev. 2014 Aug;40(7):862-71
pubmed: 24774538
Br J Cancer. 2022 Oct;127(6):1086-1096
pubmed: 35725814
Cancer Invest. 2011 Nov;29(9):585-93
pubmed: 21936625
Ann Oncol. 2012 Jul;23(7):1771-80
pubmed: 22112968
Breast Cancer Res Treat. 2008 Jun;109(3):573-9
pubmed: 17674197
JAMA. 2022 May 24;327(20):1963-1973
pubmed: 35608580
PLoS One. 2013 Sep 25;8(9):e75088
pubmed: 24086446
Br J Cancer. 2021 Oct;125(9):1285-1298
pubmed: 34462586
Br J Cancer. 2014 Jul 29;111(3):623-7
pubmed: 24945997
Med Oncol. 2022 Jul 14;39(10):142
pubmed: 35834073
Lung Cancer. 2023 May;179:107187
pubmed: 37060880
Diabetes Care. 2018 Apr;41(4):755-761
pubmed: 29351960
Tidsskr Nor Laegeforen. 2015 May 05;135(8):768-70
pubmed: 25947599
Breast Cancer Res. 2015 May 03;17:64
pubmed: 25935404
Int J Cancer. 2016 Sep 15;139(6):1281-8
pubmed: 27176735
Lancet Oncol. 2014 Sep;15(10):e461-8
pubmed: 25186049
Br J Cancer. 2023 Apr;128(6):958-966
pubmed: 36823364